Therapeutic Solutions International Continues to Expand
Chronic Traumatic Encephalopathy Intellectual Property
Portfolio
Patent for Prevention and Reversion of CTE using
"Educated" Monocytes and Progenitor Cells
OCEANSIDE, CA
-- January
22,
2019 -- InvestorsHub
NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today an
additional expansion to their CTE portfolio of intellectual
property with the filing of this new patent application.
This new and novel
invention provides a means of preventing and/or reversing
chronic traumatic
encephalopathy in a patient through
the modulation of their monocytes as well as their monocytic
progenitors.
"Injuries to the head,
in particular, traumatic brain injury (TBI) are a substantially
important public
health problem, affecting
millions of people annually in the U.S. alone. TBI is classified on
a spectrum ranging from mild to severe,
with mild TBI (mTBI)
accounting for a vast
majority of TBI cases. Notably, the incidence of
mild TBI
is commonly regarded as under-reported, particularly in the context
of sports competitions, where athletes may
wish to avoid being forced to stop participation until completion
of a formal medical evaluation and return
to play protocol is
completed" said Tim G Dixon
CEO & President of Therapeutic Solutions International,
Inc. "As a result,
mild TBI has been referred
to as a silent
epidemic that desperately
needs a voice."
"This invention relies
on the capacity of certain neurogenesis progenitor cells in the
form of "educated"
monocytes
to secrete into growth medium the growth factors and cytokines
involved in neurogenesis in a time and
concentration-dependent coordinated and
appropriate sequence," said Dr. Thomas
Ichim, Director of
Therapeutic Solutions International and
co-inventor with Mr.
Dixon.
"Most
currently tested therapeutic approaches have focused on a single
neurogenesis growth
factor delivered to the
tissue. This can be accomplished either by delivery of the end
product (e.g., protein) or by gene transfer,
using diverse vectors. However, it is believed that complex
interactions among several growth factor systems
are probably necessary for the initiation and maintenance of new
neuron formation"
added Dr.
Ichim.
"The typical head
impact in mild TBI induces rapid percussive and/or torsional
(rotational) damage to the brain, leading to bruising and
hemorrhage with direct brain cell loss, a type of injury
that is known to persist for years. Furthermore, repetitive mild
TBI is associated with serious long-term sequelae including
post-concussive syndrome and chronic
traumatic encephalopathy (CTE), the latter often leading to
cognitive impairment,
neuropsychiatric symptoms, dementia, and pugilistic parkinsonism.
Currently, there is a need to
treat CTE
with novel approaches" said Dr. James
Veltmeyer, Chief Medical Officer of Therapeutic
Solutions International. "This new technology
does just that stimulating
neuroregeneration and decreasing inflammation in
patients
with CTE."
Since September 2018
the Company has filed 3 other patent applications for CTE related
technologies. These include
"Pterostilbene and
Compositions Thereof for Prevention and Treatment of Chronic
Traumatic Encephalopathy", "Treatment of Chronic Traumatic
Encephalopathy via RNA Administration",
"Autologous Neurogenic Cells and Uses Thereof for Professional
Athletes at Risk of Chronic Traumatic Encephalopathy"
and
today's
filing titled "Prevention and Reversion of Chronic Traumatic
Encephalopathy through Administration of "Educated" Monocytes and
Progenitors Thereof". In addition to these
the Company also recently announced the licensing of mesenchymal
stem cells for use in CTE and TBI under Right To
Try.
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
at
www.therapeuticsolutionsint.com
and our
e-commerce is at www.youcanordernow.com
and for
additional info on NanoStilbene visit www.nanostilbene.com.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
Safe Harbor
Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
Contact
Information: